Musculoskeletal complications in type 1 diabetes

Mary E Larkin, Annette Barnie, Barbara H Braffett, Patricia A Cleary, Lisa Diminick, Judy Harth, Patricia Gatcomb, Ellen Golden, Janie Lipps, Gayle Lorenzi, Carol Mahony, David M Nathan, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Mary E Larkin, Annette Barnie, Barbara H Braffett, Patricia A Cleary, Lisa Diminick, Judy Harth, Patricia Gatcomb, Ellen Golden, Janie Lipps, Gayle Lorenzi, Carol Mahony, David M Nathan, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group

Abstract

Objective: The development of periarticular thickening of skin on the hands and limited joint mobility (cheiroarthropathy) is associated with diabetes and can lead to significant disability. The objective of this study was to describe the prevalence of cheiroarthropathy in the well-characterized Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort and examine associated risk factors, microvascular complications, and the effect of former DCCT therapy (intensive [INT] vs. conventional [CONV]) on its development.

Research design and methods: This cross-sectional analysis was performed in 1,217 participants (95% of the active cohort) in EDIC years 18/19 after an average of 24 years of follow-up. Cheiroarthropathy-defined as the presence of any one of the following: adhesive capsulitis, carpal tunnel syndrome, flexor tenosynovitis, Dupuytren's contracture, or a positive prayer sign-was assessed using a targeted medical history and standardized physical examination. A self-administered questionnaire (Disabilities of the Arm, Shoulder and Hand [DASH]) assessed functional disability.

Results: Cheiroarthropathy was present in 66% of subjects (64% of the INT group and 68% of the CONV group; P = 0.1640) and was associated with age, sex, diabetes duration, skin intrinsic fluorescence, HbA1c, neuropathy, and retinopathy (P < 0.005 for each). DASH functional disability scores were worse among subjects with cheiroarthropathy (P < 0.0001).

Conclusions: Cheiroarthropathy is common in people with type 1 diabetes of long duration (∼30 years) and is related to longer duration and higher levels of glycemia. Clinicians should include cheiroarthropathy in their routine history and physical examination of patients with type 1 diabetes because it causes clinically significant functional disability.

Trial registration: ClinicalTrials.gov NCT00360815 NCT00360893.

© 2014 by the American Diabetes Association.

Figures

Figure 1
Figure 1
Association of prevalence of cheiroarthropathy by tertiles of time-weighted HbA1c during the DCCT/EDIC (1983–2011). Subjects could report more than one type of cheiroarthropathy. The P values estimate the HbA1c group differences calculated using the contingency χ2 test for categorical variables. Twenty subjects were missing an HbA1c measurement at EDIC year 18.

References

    1. Cagliero E, Apruzzese W, Perlmutter GS, Nathan DM. Musculoskeletal disorders of the hand and shoulder in patients with diabetes mellitus. Am J Med 2002;112:487–490
    1. Rosenbloom AL, Silverstein JH. Connective tissue and joint disease in diabetes mellitus. Endocrinol Metab Clin North Am 1996;25:473–483
    1. Kim RP, Edelman SV, Kim DD. Musculoskeletal complications of diabetes mellitus. Clin Diabetes 2001;19:132–135
    1. Redmond CL, Bain GI, Laslett LL, McNeil JD. Hand syndromes associated with diabetes: impairments and obesity predict disability. J Rheumatol 2009;36:2766–2771
    1. Ramchurn N, Mashamba C, Leitch E, et al. Upper limb musculoskeletal abnormalities and poor metabolic control in diabetes. Eur J Intern Med 2009;20:718–721
    1. Kemmis K. Common musculoskeletal disorders in older adults with diabetes. Top Geriatr Rehabil 2010;26:264–272
    1. Cole A, Gill TK, Shanahan EM, Phillips P, Taylor AW, Hill CL. Is diabetes associated with shoulder pain or stiffness? Results from a population based study. J Rheumatol 2009;36:371–377
    1. Smith LL, Burnet SP, McNeil JD. Musculoskeletal manifestations of diabetes mellitus. Br J Sports Med 2003;37:30–35
    1. Nathan DM. The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Ann Intern Med 1996;124:86–89
    1. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992;15:1835–1843
    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
    1. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99–111
    1. Beaton DE, Katz JN, Fossel AH, Wright JG, Tarasuk V, Bombardier C. Measuring the whole or the parts? Validity, reliability, and responsiveness of the Disabilities of the Arm, Shoulder and Hand outcome measure in different regions of the upper extremity. J Hand Ther 2001;14:128–146
    1. Schoneveld K, Wittink H, Takken T. Clinimetric evaluation of measurement tools used in hand therapy to assess activity and participation. J Hand Ther 2009;22:221–235; quiz 236
    1. The DCCT Research Group. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 1987;33:2267–2271
    1. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48:870–880
    1. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type 1 diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986;314:403–408
    1. Cleary PA, Braffett BH, Orchard T, et al. DCCT/EDIC Research Group Clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Technol Ther 2013;15:466–474
    1. Abate M, Schiavone C, Salini V, Andia I. Management of limited joint mobility in diabetic patients. Diabetes Metab Syndr Obes 2013;6:197–207
    1. American Diabetes Association Standards of medical care in diabetes–2008. Diabetes Care 2008;31(Suppl. 1):S12–S54
    1. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Nathan DM, Zinman B, Cleary PA, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009;169:1307–1316

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться